Dallas, TX 8/4/2009 10:56:58 PM
NVSR, ALRX, BNVI, WNC, KERX, August 4 Daily Market Movers Digest Report from OTCPicks.com
OTCPicks.com’s Daily Small Cap and Microcap Newsletter presents a range of the hottest small cap stocks on trading on the OTC and OTCBB markets. In addition to our Newsletters, OTCPicks.com is quickly becoming the premier community destination for small cap and microcap traders to meet up and discuss their top stock picks. Visit http://www.otcpicks.com/microcap.htm today to join this growing community. Our Stocks to Watch today include NavStar Technologies Inc. (OTC: NVSR), AlphaRx Inc. (OTCBB: ALRX), Bionovo Inc. (Nasdaq: BNVI), Wabash National Corp. (NYSE: WNC) and Keryx Biopharmaceuticals Inc. (Nasdaq: KERX). For the complete newsletter please visit: http://www.otcpicks.com/daily-market-movers/index.php For more in-depth coverage of small cap stocks visit http://www.otcpicks.com/microcap.htm NAVSTAR TECHNOLOGIES INCORPORATED (OTC: NVSR) "Up as much as 52% in morning trading; sixth consecutive day of double-digit gains" Company Profile: http://www.otcpicks.com/navstar-technologies/navstar-technologies.htm NavStar is focused on the creation of GPS products and services that provide wireless tracking of vehicles, equipment, and other valuable and personal assets. The goal is to be a total solutions provider. ALPHARX INCORPORATED (OTCBB: ALRX) "Up 3.33% in morning trading" Company Profile: http://www.otcpicks.com/alpharx/alpharx.htm AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development. BIONOVO INCORPORATED (NASDAQ: BNVI) "Up 82.75% in morning trading" Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. WABASH NATIONAL CORPORATION (NYSE: WNC) "Up 44.36% in morning trading" Headquartered in Lafayette, Ind., Wabash National® Corporation (NYSE:WNC - News) is one of the leading manufacturers of semi trailers in North America. Established in 1985, the Company specializes in the design and production of dry freight vans, refrigerated vans, flatbed trailers, drop deck trailers, dump trailers, truck bodies and intermodal equipment. Its innovative core products are sold under the DuraPlate®, ArcticLite®, FreightPro(TM) Eagle® and Benson(TM) brand names. The Company operates two wholly-owned subsidiaries: Transcraft® Corporation, a manufacturer of flatbed, drop deck, dump trailers and truck bodies; and Wabash National Trailer Centers, trailer service centers and retail distributors of new and used trailers and aftermarket parts throughout the U.S. KERYX BIOPHARMACEUTICALS INCORPORATED (NASDAQ: KERX) "Up 4.35% in morning trading" Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City. About OTCPicks.com OTCPicks.com is fast becoming the premier Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Research Reports authored by our financial writers. We publish our Daily Market Movers Digest Newsletter to opt-in investor members. OTCPicks.com presents the latest information for the discerning small cap and microcap investor. The site features informative articles on microcap investing, the top penny stock picks, and a wealth of small cap research on vertical markets. To feature a company on OTCPicks.com, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com. Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Disclosure: OTCPicks.com has been compensated eight thousand dollars by a third party (Mickey Reno) for NVSR advertising and promotional services. OTCPicks.com has been compensated seven thousand five hundred dollars by a third party (Blue Wave Advisors) for ALRX advertising and promotional services. OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.
